July 1st 2025
Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.
FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR Status
August 16th 2022Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.
Potential Biomarkers Identified in Post-Hoc Analysis of Apalutamide Plus ADT in mCRPC
June 7th 2022A post-hoc analysis of the phase 3 TITAN trial revealed potential biomarkers that may predict overall survival in patients with metastatic castration-resistant prostate cancer receiving apalutamide plus androgen deprivation therapy.